GURU.Markets stock price, segment price, and overall market index valuation
The company's share price iCAD Inc.
Shares of iCoreConnect, a company providing cloud-based software for dentists and doctors, reflect its efforts to grow in this niche market. Their price trajectory depends on the company's ability to grow its subscriber base.
Share prices of companies in the market segment - Cancer cure
iCAD, Inc. develops AI-based solutions for the early detection and treatment of cancer, primarily for mammogram analysis. We've categorized it under "Cancer Treatment." The chart below shows how investors view the use of AI in cancer diagnostics.
Broad Market Index - GURU.Markets
iCAD is a company that develops and markets AI-based software for medical image analysis, primarily for cancer detection. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with iCAD's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ICAD - Daily change in the company's share price iCAD Inc.
For iCAD, Inc., which uses AI for cancer diagnosis, daily volatility reflects sensitivity to news about the approval and implementation of its technologies. This metric is an indicator of demand for AI solutions in medicine.
Daily change in the price of a set of shares in a market segment - Cancer cure
iCAD develops AI-powered solutions for the early detection of cancer, particularly breast cancer. The AI-based medical diagnostics sector is rapidly growing. The chart below shows the volatility in this niche, reflecting the high potential and risks associated with ICAD's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
iCAD uses artificial intelligence to analyze medical images and diagnose cancer early. This medtech company's stock reflects the growing role of AI in medicine. Its volatility is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization iCAD Inc.
iCAD, Inc.'s year-over-year performance is a story about the application of AI in cancer diagnostics. Its 12-month market cap growth reflects demand for its software, which helps radiologists analyze mammograms to detect breast cancer. Its valuation is a bet that its AI solutions will become the standard in radiology.
Annual dynamics of market capitalization of the market segment - Cancer cure
iCAD, Inc. is a company using AI to analyze medical images for cancer detection. This chart shows how its innovative technology, the struggle for widespread adoption in hospitals, and competition are impacting its performance in the medical diagnostics sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
iCAD, a developer of AI-powered software for cancer diagnostics, is at the forefront of medical technology. Its year-over-year market capitalization dynamics demonstrate how investors view the potential of AI in healthcare. Successful clinical implementation and regulatory approval are key drivers capable of outweighing overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization iCAD Inc.
iCAD is a manufacturer of AI-based cancer diagnostic systems. Its monthly growth reflects the pace of clinical adoption of its technologies. Quarterly sales reports and news of FDA approvals for new algorithms are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the medical technology sector, particularly AI-based cancer diagnostics. For iCAD, a leader, this serves as a backdrop. Its movements demonstrate how the pace of adoption of its technologies in clinics and changes in reimbursement rates impact the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
iCAD is a company developing AI-based solutions for early cancer diagnosis using medical images. The company's growth depends on the implementation of its technologies in clinics. A full-market chart shows how strong its own growth trend, driven by medical innovation, allows iCAD shares to move independently of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization iCAD Inc.
iCAD, Inc. provides AI-powered software for detecting cancer in medical images (such as mammograms). Its weekly stock price is driven by the pace of adoption of its technology in clinics and competition.
Weekly dynamics of market capitalization of the market segment - Cancer cure
iCAD develops AI-based solutions for early cancer detection, particularly breast cancer. The company is at the forefront of the digitalization of medicine. The chart below shows whether iCAD's share price fluctuations are a reaction to the implementation of its technologies in clinics or reflect broader trends in the medical AI sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
iCAD is a company in the field of AI-powered medical diagnostics. This is a growth story, and shares of such companies are typically more volatile than the market. This chart will help you assess how strongly investor expectations for AI in medicine are driving the company's stock price movement.
Market capitalization of the company, segment and market as a whole
ICAD - Market capitalization of the company iCAD Inc.
iCAD's market capitalization chart reflects its focus on developing AI-based software for detecting cancer in medical images. Its volatile chart shows how investors weigh the enormous potential of its technology against the challenges of commercializing it and integrating it into radiologists' workflows.
ICAD - Share of the company's market capitalization iCAD Inc. within the market segment - Cancer cure
iCAD develops AI-based software for detecting cancer in medical images. Its market share in the medtech sector is small, but it is a leader in the niche of computer-aided breast cancer diagnostics. The chart shows how the market views its AI solutions and their implementation in clinics.
Market capitalization of the market segment - Cancer cure
Below is a chart of the total market capitalization of the medical diagnostics sector. iCAD is a technology company pioneering the use of AI for medical image analysis, particularly in mammography. The growth of this market reflects how AI is becoming a "second opinion" for doctors, and iCAD is at the forefront of this revolution.
Market capitalization of all companies included in a broad market index - GURU.Markets
iCAD provides AI-powered software for medical image analysis, helping to detect cancer at early stages. Its market cap reflects its bet on AI in diagnostics. The chart below shows the growing economic importance of the AI-radiology sector.
Book value capitalization of the company, segment and market as a whole
ICAD - Book value capitalization of the company iCAD Inc.
iCAD's foundation is its intellectual property, which covers software that uses artificial intelligence to detect cancer in medical images (mammography, tomography). This chart tells the story of a medical AI pioneer investing in its algorithms to make cancer diagnosis more accurate and effective.
ICAD - Share of the company's book capitalization iCAD Inc. within the market segment - Cancer cure
iCAD develops AI for medical image analysis. The chart shows its share of physical IT and R&D assets. Its resources include computing power for training algorithms and laboratories where solutions for early cancer detection are created.
Market segment balance sheet capitalization - Cancer cure
iCAD develops AI-powered solutions for early cancer detection. Their product is software, not medical equipment. A book value chart shows a typical picture for a software developer: minimal tangible assets and a focus on an intangible product that improves diagnostics.
Book value of all companies included in the broad market index - GURU.Markets
iCAD's assets include R&D centers and IT infrastructure for developing AI-based software for detecting cancer in medical images. The chart shows how this technological and material foundation has grown.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - iCAD Inc.
iCAD develops AI-based software for cancer diagnosis using medical images. Its main asset is its algorithms. The chart below shows the market premium paid for its technological leadership. This trend reflects the speed of AI adoption in medicine and the company's sales success.
Market to book capitalization ratio in a market segment - Cancer cure
iCAD develops AI-based software to aid in early cancer detection through medical image analysis. Its value lies in its algorithms. The chart shows how much its market valuation, based on the potential of AI in medicine, exceeds its tangible assets.
Market to book capitalization ratio for the market as a whole
iCAD develops AI-based software for cancer diagnostics. The company's value lies in its algorithms and patents. This chart shows that the market valuation is many times higher than the book value, as investors are paying for technology that could dramatically improve early cancer detection.
Debts of the company, segment and market as a whole
ICAD - Company debts iCAD Inc.
iCAD, Inc. develops AI-based software for early cancer detection using medical images. This chart shows the financial status of the company, which is investing in cutting-edge technologies. Raising capital is necessary to fund R&D and commercialize its radiology products.
Market segment debts - Cancer cure
iCAD develops AI-based software for medical image analysis, primarily for cancer detection. This is a cutting-edge field in MedTech. This chart shows how the company finances its expensive development and efforts to gain regulatory approval and clinical implementation.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio iCAD Inc.
iCAD provides AI-based software for cancer diagnostics. This chart shows its financial structure. For a medical technology company, it's important to have resources for R&D and regulatory approvals. High debt can limit these opportunities.
Market segment debt to market segment book capitalization - Cancer cure
iCAD develops AI-powered solutions for early cancer detection. This chart shows the debt burden in the medical diagnostics sector. It helps understand how tech companies in this important field finance their research, development, and regulatory approval processes.
Debt to book value of all companies in the market
iCAD develops AI-based software for early cancer detection, primarily breast cancer. This is an important niche in medical technology. This chart of total market debt helps understand how the company finances its expensive AI R&D and how its strategy compares to other tech companies.
P/E of the company, segment and market as a whole
P/E - iCAD Inc.
iCAD develops AI-based software that helps radiologists detect cancer in medical images such as mammograms. This chart shows how investors view the application of AI in medicine. The trend depends on the implementation of its products in hospitals and evidence of their clinical effectiveness.
P/E of the market segment - Cancer cure
iCAD is a company that develops AI-based software for cancer diagnosis and treatment. Their solutions help radiologists detect cancer at early stages in medical images. This chart shows the average valuation for the oncology sector, reflecting how investors value the use of AI to improve cancer diagnosis.
P/E of the market as a whole
iCAD is a company developing AI-based software for early cancer detection using medical images. Its valuation is a bet on the adoption of AI in radiology. It is not tied to general economic cycles, but depends on its ability to demonstrate that its algorithms improve diagnostic accuracy and enhance physician efficiency.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company iCAD Inc.
iCAD is a medical technology company developing AI-based solutions for cancer detection, particularly breast cancer, in mammograms. This chart shows future revenue expectations based on the adoption of its AI tools in radiology practices worldwide.
%20P%2FE%20iCAD%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-iCAD-Inc.&v=1772572462249 "Chart of the company's future (projected) P/E iCAD Inc.")
Future (projected) P/E of the market segment - Cancer cure
iCAD provides AI-powered medical image analysis software that helps radiologists detect cancer. This chart shows general expectations for the medical technology sector. ICAD's position relative to the average reflects whether investors believe its AI solutions will become integral to cancer screening and diagnosis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772572462289 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
iCAD, Inc. provides AI-powered software for cancer detection and diagnosis. The company's solutions help radiologists analyze medical images, such as mammograms, improving accuracy. This chart of overall market expectations provides context for assessing the rapidly growing medical AI market, of which iCAD is a pioneer.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772572462293 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit iCAD Inc.
iCAD, Inc. develops AI-based software for medical image analysis, specifically for the early detection of breast cancer in mammograms. The revenue chart shows how successfully the company is selling its solutions to hospitals and radiology centers.
Profit of companies in the market segment - Cancer cure
iCAD, Inc. develops AI-based solutions for cancer detection and treatment, particularly breast cancer. Its technologies help radiologists improve diagnostic accuracy. This chart represents the overall revenue stream in the cancer treatment sector. It shows how the implementation of AI and advanced diagnostic tools impacts efficiency and profitability in oncology.
Overall market profit
iCAD, Inc. develops AI-based solutions for the diagnosis and treatment of cancer, particularly breast cancer. Demand for its technology is driven by the desire for early and accurate diagnosis. Overall economic growth, reflected in this chart, allows medical institutions to invest more in advanced technologies like iCAD's.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company iCAD Inc.
iCAD provides AI-based software for cancer detection in medical imaging, particularly mammography. This chart shows analysts' future revenue expectations, which depend on the adoption of AI technologies in radiology and the company's ability to demonstrate the clinical and economic value of its products.
%20profit%20of%20the%20company%20iCAD%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-iCAD-Inc.&v=1772572462526 "Graph of future (projected) profit of the company iCAD Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
iCAD develops AI-based software for medical image analysis, specifically for the early detection of breast cancer in mammograms. The company's success depends on the implementation of its technologies in clinics. This chart shows forecasts for the medical technology sector, helping to assess how iCAD is improving cancer diagnostics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772572462542 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
iCAD, Inc. develops AI-based solutions for cancer diagnosis and treatment. Demand for its technologies depends on healthcare budgets and the desire to improve diagnostic accuracy. The overall economic situation, reflected in this graph, can influence the speed of purchasing decisions at clinics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772572462568 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - iCAD Inc.
iCAD develops AI-based software for early cancer detection using medical images. This chart shows the high premium investors are paying for its cutting-edge technology. The high multiple reflects the belief that AI will become standard in radiology and help save lives.
P/S market segment - Cancer cure
iCAD, Inc. develops AI-based solutions for cancer detection and treatment, particularly breast cancer. Its revenue comes from sales of its medical image analysis software. This chart for the medical devices and AI sector helps gauge how investors view iCAD's technology and its role in early cancer detection.
P/S of the market as a whole
iCAD provides AI-powered software for medical image analysis, specifically for the early detection of breast cancer in mammograms. This market valuation chart helps understand the premium investors are willing to pay for cutting-edge technologies that can save lives and improve diagnostics.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company iCAD Inc.
iCAD provides advanced AI-powered software solutions for the early detection and treatment of cancer, particularly breast cancer. Its technology helps radiologists analyze medical images. This chart shows how investors estimate future revenue from its software sales, reflecting the growing adoption of AI in healthcare.
%20P%2FS%20iCAD%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-iCAD-Inc.&v=1772572462792 "The graph of the company's future (projected) P/S iCAD Inc.")
Future (projected) P/S of the market segment - Cancer cure
iCAD develops AI-based solutions for cancer detection in medical imaging, particularly mammography. The company's valuation reflects investors' belief that AI can significantly improve the accuracy and efficiency of cancer diagnostics, as well as its ability to successfully commercialize and sell its technologies to hospitals.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772572462822 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
iCAD, Inc. develops AI-based solutions for early cancer diagnosis using medical images. The company is at the intersection of AI and medicine. The future revenue growth expectations reflected here are largely based on the breakthroughs enabled by iCAD's technology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772572462867 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales iCAD Inc.
iCAD provides AI-based software solutions for cancer diagnosis and treatment. This chart shows revenue from sales of its mammography and CT software, which helps radiologists detect cancer at early stages. The implementation of AI in medicine is driving growth.
Sales of companies in the market segment - Cancer cure
iCAD (ICAD) provides AI-based software for cancer diagnosis and treatment, primarily breast cancer. Its solutions help radiologists detect tumors at early stages. This chart shows revenue in the oncology sector. iCAD technologies play a significant role in improving the accuracy and effectiveness of cancer screening.
Overall market sales
iCAD develops AI-based software for the diagnosis and treatment of cancer, particularly breast cancer. Demand for its products depends on the implementation of AI in radiology. This trend in overall economic activity impacts hospital budgets. During periods of growth, they invest more actively in advanced technologies to improve diagnostic accuracy and efficiency.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company iCAD Inc.
iCAD, Inc. develops AI-based solutions for the early detection and treatment of cancer, particularly breast cancer. The company's sales depend on the adoption of its software in hospital radiology departments. This chart reflects analyst revenue forecasts, which are an indicator of the speed of adoption of AI technologies in medical diagnostics.
%20sales%20of%20the%20company%20iCAD%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-iCAD-Inc.&v=1772572463063 "Schedule of future (projected) sales of the company iCAD Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
iCAD provides AI-based software for cancer detection in medical image analysis. This graph's forecast segments future revenue, likely by mammography and CT products. This shows how analysts estimate demand for AI solutions in radiology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772572463088 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
iCAD, Inc. develops AI-based solutions for cancer diagnosis using medical images, primarily mammograms. Its technology helps radiologists detect cancer at an early stage. This graph shows overall healthcare costs, and the implementation of iCAD systems in clinics is an indicator of how AI is transforming medical diagnostics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772572463139 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality iCAD Inc.
iCAD, Inc. develops AI-based solutions for early cancer detection, primarily for mammogram analysis. The company's profitability depends on the implementation of its technologies in hospitals and radiology centers. The chart shows how the company, by helping doctors make more accurate diagnoses, aims to turn its AI algorithms into a profitable business.
Market segment marginality - Cancer cure
iCAD is a company developing AI-based software for cancer detection and diagnosis, particularly breast cancer, using mammograms. This chart shows the company's profitability. Success depends on the clinical effectiveness of its algorithms and their implementation in radiology practice.
Market marginality as a whole
iCAD, Inc. develops AI-based solutions for cancer diagnosis and treatment, particularly breast cancer. Demand for its technologies depends on hospital budgets. This overall profitability chart reflects their financial capabilities. Economic stability allows medical institutions to invest in advanced technologies to improve diagnostics.
Employees in the company, segment and market as a whole
Number of employees in the company iCAD Inc.
iCAD develops AI-based software that assists radiologists in the early detection of cancer, particularly breast cancer. This graphic shows a team of engineers and data scientists creating tools that improve the accuracy and efficiency of medical diagnostics.
Share of the company's employees iCAD Inc. within the market segment - Cancer cure
iCAD develops AI-based solutions for early cancer detection using medical images. In this cutting-edge field, the company employs a combination of AI engineers and specialists working with radiologists. This chart shows the human and intellectual capital the company is investing in creating life-saving technologies.
Number of employees in the market segment - Cancer cure
iCAD, Inc. provides AI-powered software solutions for early cancer detection. This chart, showing employment in the cancer treatment sector, illustrates how technology is changing diagnostics. For iCAD, the growing number of oncologists and radiologists using AI means an expanding market for their software, which helps improve the accuracy and effectiveness of screening.
Number of employees in the market as a whole
iCAD develops AI-based solutions for early cancer detection using medical images. The implementation of such technologies depends on the budgets of medical institutions. The growth in overall employment, reflected in this graph, supports healthcare system funding, allowing clinics to invest in advanced diagnostic tools to improve accuracy and efficiency.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company iCAD Inc. (ICAD)
iCAD (ICAD) develops AI-powered software for cancer diagnostics (e.g., mammogram analysis). It's a MedTech business built on AI. This chart shows the market value of their algorithms and patents. A high cost per employee is normal, as their software (intellectual capital) scales across thousands of clinics without increasing staff.
%20of%20the%20company%20iCAD%20Inc.%20(ICAD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-iCAD-Inc.-ICAD&v=1772572463422 "Chart of market capitalization per employee (in thousands of dollars) of the company iCAD Inc. (ICAD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
iCAD develops AI-powered systems for early cancer detection. In the MedTech AI space, the value lies in the algorithms. This chart shows how the market values its technology and its ability to improve diagnostics, which translates into high per-developer value.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772572463467 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
iCAD is a MedTech company developing AI-based software for early-stage cancer detection, particularly breast cancer. In this chart, iCAD demonstrates how AI in medicine can create enormous value, leading to high valuations per employee, as their software helps doctors save lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772572463675 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company iCAD Inc. (ICAD)
iCAD provides AI-powered solutions for cancer diagnostics, primarily breast cancer (mammogram analysis). It's a high-tech medical business (SaaS/MedTech). This chart shows how popular their software is with clinics and the margins it allows, generating high profit per employee.
%20Chart%20iCAD%20Inc.%20(ICAD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-iCAD-Inc.-ICAD&v=1772572463785 "Company Profit Per Employee (in thousands of dollars) Chart iCAD Inc. (ICAD)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
iCAD, Inc. develops AI-based solutions for the early detection of cancer, particularly breast cancer. In medical AI, value is created through the accuracy of algorithms and the work of the development team. This chart shows how the company monetizes its technologies, improving the efficiency of radiologists and generating revenue.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772572464027 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
iCAD, Inc. is a medical technology company developing AI-powered software for early cancer detection, primarily for mammography (breast cancer). This chart, showing average profit per employee across all industries, helps investors assess the high-margin nature of the AI medical technology sector, where algorithms and R&D are essential, per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772572464137 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee iCAD Inc. (ICAD)
iCAD provides AI-powered software for the early detection of cancer, particularly breast cancer. In a SaaS business, revenue per employee is an indicator of scalability. The graph shows how successfully the company is selling its solutions to radiologists and hospitals, helping them improve diagnostic accuracy and efficiency.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-iCAD-Inc.-ICAD&v=1772572464162 "Sales chart per company employee iCAD Inc. (ICAD)")
Sales per employee in the market segment - Cancer cure
iCAD (ICAD) develops and markets AI-powered software for early cancer detection, primarily for mammogram analysis (breast cancer). This chart shows the average revenue per employee in this segment. It helps assess how effectively iCAD generates sales of its diagnostic software using its team.
Sales per employee for the market as a whole
iCAD (ICAD) develops AI-powered software for cancer diagnostics, primarily for mammogram analysis (breast cancer). It is a MedTech/SaaS company. This metric demonstrates how successfully the company sells its software (subscription or license) to hospitals and diagnostic centers based on its engineering and sales staff.
Short shares by company, segment and market as a whole
Shares shorted by company iCAD Inc. (ICAD)
iCAD (ICAD) develops AI solutions for cancer detection (primarily breast cancer). Despite AI's promise, the company struggles to achieve widespread adoption. This chart shows short interest. The rise in bearish rates reflects concerns about slow commercialization, difficulties receiving reimbursement from insurers, and high cash burn. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-iCAD-Inc.-ICAD&v=1772572464393 "Short Shares Chart for the Company iCAD Inc. (ICAD)")
Shares shorted by market segment - Cancer cure
iCAD (ICAD) develops AI-powered solutions for early cancer detection, particularly in mammography. The chart below shows a general short position on the "AI in Medicine" sector. It illustrates how skeptical investors are about the speed of AI adoption in clinical practice or reimbursement models.
Shares shorted by the overall market
iCAD produces AI-powered software for early cancer detection (mammography). It's a medical technology company dependent on hospital capital expenditures. This chart measures general fear. When investors are afraid, they expect hospitals to cut budgets. Purchases of new software, even innovative ones, are delayed, which hurts the growth of small companies like ICAD.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator iCAD Inc. (ICAD)
iCAD is a "MedTech" company providing AI solutions for analyzing mammograms and detecting breast cancer. It's AI that saves lives. This indicator measures the "temperature" of the hype surrounding AI in medicine. It "heats up" on news of their AI's superiority over radiologists and "cools down" in anticipation of increased sales.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-iCAD-Inc.-ICAD&v=1772572464586 "RSI 14 indicator chart for the company's stock iCAD Inc. (ICAD)")
RSI 14 Market Segment - Cancer cure
iCAD, Inc. is a MedTech company that provides cutting-edge AI-powered solutions for cancer detection. Its software helps radiologists detect breast cancer at early stages. This graph shows the overall "temperature" in the AI and oncology sectors. It helps us understand whether ICAD's momentum is part of the general AI hype or the result of its clinical successes.
RSI 14 for the overall market
iCAD (ICAD), a cancer diagnostics company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ICAD (iCAD Inc.)
iCAD is a medical technology company developing AI solutions for cancer diagnostics. Its software helps radiologists detect breast cancer (mammography) and prostate cancer (MRI). This chart shows the average 12-month price target from analysts, based on their belief in the adoption of AI in diagnostics and sales growth.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ICAD-iCAD-Inc.&v=1772572464747 "A chart showing analyst consensus forecasts for the expected stock price. ICAD (iCAD Inc.)")
The difference between the consensus estimate and the actual stock price ICAD (iCAD Inc.)
iCAD (ICAD) is an AI-powered "second opinion" service. Their software helps radiologists detect breast cancer on mammograms faster and more accurately. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the implementation of this AI diagnostics in clinics and their subscription-based SaaS model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ICAD-iCAD-Inc.&v=1772572464778 "A chart showing the difference between the consensus forecast and the actual stock price. ICAD (iCAD Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
iCAD is a "detective" in the fight against cancer. The company provides cutting-edge AI-powered software that helps radiologists detect breast cancer earlier and more accurately. This chart reflects the collective opinion of Gkov analysts on the *entire* AI in Medicine and oncotech sector. It shows whether experts believe AI diagnostics will become the standard of care.
Analysts' consensus forecast for the overall market share price
iCAD is a company at the intersection of AI and medicine. They develop software that analyzes mammograms for the early detection of breast cancer. This chart shows overall market sentiment. For iCAD, whose business is implementing new diagnostic technology, overall optimism (the rising chart) is important for funding and hospitals' willingness to invest in AI.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index iCAD Inc.
iCAD is an AI detective for breast cancer. Their signature feature is a SaaS platform (software) that uses AI to analyze mammograms. Their software helps radiologists detect signs of cancer early and assess risk. This chart summarizes their implementation history. It reflects their (slow) growth (ARR) and their (uphill) battle for reimbursement from insurance companies.
AKIMA Market Segment Index - Cancer cure
iCAD is an AI-powered cancer diagnostician. Their software analyzes mammograms and CT scans, helping radiologists detect breast and prostate cancer at the earliest stages. This graph compares their composite index to the sector, showing how their AI-powered cancer treatment outperforms the competition.
The AKIM Index for the overall market
iCAD is a MedTech company providing solutions for cancer detection and treatment (AI for mammography, radiation therapy). This chart, reflecting the market average, is a backdrop. It helps assess how ICAD, which is implementing AI in oncology, compares to overall macroeconomic trends and clinic budgets.
